Thus, it is conceivable that CLDN2 expression in triple-negative breast cancer cells is controlled by an AP-1 complex composed of c-Fos and another Jun family member, such as Jun B or JunD. The gene discussed is CLDN2; the disease is triple-negative breast carcinoma.